Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

3.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
3.2K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Evaluation of Symptom Burden and Medication Use in Seasonal Allergic Rhinitis/Rhinoconjunctivitis Patients Considering Allergen-Specific Immunotherapy.

Journal of clinical medicine·2026
Same author

Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Correction: Gerstlauer et al. TAPAS-A Prospective, Multicentre, Long-Term Cohort Study in Children, Adolescents and Adults with Seasonal Allergic Rhinitis-Design and Early Results. <i>J. Clin. Med.</i> 2025, <i>14</i>, 2609.

Journal of clinical medicine·2025
Same author

Allergen Immunotherapy with Depigmented-Polymerised Cat Allergoid Is Safe and Well-Tolerated in Patients with Allergic Rhinitis/Rhinoconjunctivitis.

Journal of clinical medicine·2025
Same author

Clinical Efficacy of One Short Course of Mannan-Conjugated Birch Pollen Allergoid Immunotherapy: A Comparative Evaluation After Prior Placebo Treatment.

Journal of clinical medicine·2025
Same author

TAPAS-A Prospective, Multicentre, Long-Term Cohort Study in Children, Adolescents and Adults with Seasonal Allergic Rhinitis-Design and Early Results.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Apr 25, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.4K

CCR1 and CCR2 antagonists.

Henning W Zimmermann, Viktor Sterzer, Hacer Sahin1

  • 1Medical Department III, University Hospital Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany. hasahin@ukaachen.de.

Current Topics in Medicinal Chemistry
|August 28, 2014
PubMed
Summary
This summary is machine-generated.

Chemokine receptors CCR1 and CCR2 are crucial for inflammation and host defense. Targeting these receptors with antagonists, despite past clinical trial failures, offers potential for new therapeutic strategies.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.4K
An Analytical Tool that Quantifies Cellular Morphology Changes from Three-dimensional Fluorescence Images
10:00

An Analytical Tool that Quantifies Cellular Morphology Changes from Three-dimensional Fluorescence Images

Published on: August 31, 2012

13.9K

Related Experiment Videos

Last Updated: Apr 25, 2026

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.4K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.4K
An Analytical Tool that Quantifies Cellular Morphology Changes from Three-dimensional Fluorescence Images
10:00

An Analytical Tool that Quantifies Cellular Morphology Changes from Three-dimensional Fluorescence Images

Published on: August 31, 2012

13.9K

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemokines are small proteins regulating leukocyte infiltration during inflammation.
  • Over 40 human chemokines bind to approximately 18 G-protein-coupled receptors.
  • CC chemokine receptors CCR1 and CCR2 are key players in inflammatory and host defense processes.

Purpose of the Study:

  • To review the role of CC chemokine receptors CCR1 and CCR2 in inflammation and host defense.
  • To discuss the therapeutic potential of targeting CCR1 and CCR2.

Main Methods:

  • Literature review of chemokine and chemokine receptor functions.
  • Analysis of clinical trial data for CCR1 and CCR2 antagonists.
  • Synthesis of biological effects and therapeutic strategies.

Main Results:

  • CCR1 and CCR2 play critical, non-redundant roles in immune responses.
  • Specific antagonists for CCR1 and CCR2 have been developed and tested in human trials.
  • Most CCR1 and CCR2 antagonist trials have not shown significant clinical efficacy to date.

Conclusions:

  • Despite past setbacks, understanding the biological roles of CCR1 and CCR2 is vital.
  • New therapeutic strategies targeting these chemokine receptors may emerge.
  • Further research could optimize the development of successful therapeutics for inflammatory and infectious diseases.